During these days coagulopathies will be on the spotlight around the globe because of two important focuses.The first focus was the ‘International Conference on congenital coagulopathies and rare diseases’ that took place in Jaen, Spain, during May 9-10.
The second reason is the World Hemophilia Foundation World Congress, which will be taking place May 11-15 in Melbourne, Australia. Both conferences seek to provide insight and cutting-edge advances on the topic of clotting disorders. WFH, according to their organizers, will have with two key areas of emphasis for the next years: education and data collection and analysis. This includes collecting data on specific research questions to build an evidence base for better care.
A clotting disorder (or bleeding disorder) is a condition in which the blood’s ability to clot (coagulate) is impaired by a deficiency of a clotting factor. This condition can cause prolonged or excessive bleeding, which may occur spontaneously or following an injury or medical and dental procedures. The Report on the WFH Annual Global Survey 2012 includes selected demographic and other data on people with hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders throughout the world. An update on this survey, which now includes data on more than 90 percent of the world’s population, identified 274,000 people with bleeding disorders in 109 countries.
Both congresses have brought special attention to the treatment of these diseases, at all levels, also getting special attention on bringing these treatments to developing countries. With this concept in mind, Medtep has leveraged the opportunities of these two events to release a new project sponsored by Grifols, which is a Catalan multinational pharmaceutical and chemical company that is producer of, especially, blood plasma-based products, a field in which it is the European leader and third-largest worldwide. The project uPatient Hemophilia was developed to add a management environment for patients with Hemophilia A, B or von Willebrand disease . The three objectives of the platform are: 1) Track all the information related to the treatment -vials, bleeds, activities, or set up and receive alerts for infusions or events-, 2) Share all this information to the patient’s healthcare team and 3) learn from this. This final objective is related to the multi-pathological condition of this type of patients. This is, firstly patients who learn to prevent will have a better life quality and, secondly, patients will be able to use uPatient for other follow-ups they might need, thus acquiring a health monitoring environment that can help and empower them in a transversal manner.
If you want to know more about uPatient Hemophilia or register to the platform please visit https://hemophilia.upatient.com/info
Also, uPatient Hemophilia wants to grow by offering more functionalities every time. If you have a specific clotting disorder or hemophilia type that is not monitored please contact us.